PTH suppression by calcitriol does not predict off‐target actions in experimental CKD

PTH suppression by calcitriol does not predict off‐target actions in experimental CKD

Abstract Vitamin D receptor agonist (VDRA) therapy for PTH suppression is a mainstay for patients with severe CKD. Calcitriol (1,25‐(OH)2D3) is a former first‐line VDRA in CKD treatment. However, a consequence of its use in CKD is accelerated vascular calcification (VC). An experimental CKD model wa...

Full description

Bibliographic Details
Main Authors: Bruno A. Svajger, Cynthia M. Pruss, Kimberly J. Laverty, Jason G. E. Zelt, Glenville Jones, Martin Kaufmann, Martin Petkovich, Rachel M. Holden, Michael A. Adams
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Pharmacology Research & Perspectives
Subjects:
Calcitriol
CKD
PTH suppression
vascular pathology
Online Access:https://doi.org/10.1002/prp2.605

Internet

https://doi.org/10.1002/prp2.605

Similar Items